Mohammad Abu Zaid1, Paul C Dinh1, Patrick O Monahan1, Chunkit Fung2, Omar El-Charif3, Darren R Feldman4, Robert J Hamilton5, David J Vaughn6, Clair J Beard7, Ryan Cook1, Sandra Althouse1, Shirin Ardeshir-Rouhani-Fard1, Howard D Sesso8, Robert Huddart9, Taisei Mushiroda10, Michiaki Kubo10, M Eileen Dolan3, Lawrence H Einhorn1, Sophie D Fossa11, Lois B Travis1. 1. Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. 2. University of Rochester Medical Center, James P. Wilmot Cancer Institute, Rochester, New York. 3. Department of Medicine, University of Chicago, Chicago, Illinois. 4. Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Division of Urology, Princess Margaret Cancer Centre, Toronto, Ontario. 6. Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 7. Department of Radiation Oncology, Dana-Farber Cancer Institute, and. 8. Divisions of Preventive Medicine and Aging, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 9. The Royal Marsden Hospital, London, United Kingdom. 10. The RIKEN Center for Integrative Medical Science, Yokohama, Japan; and. 11. Department of Oncology, Oslo University Hospital, Radium Hospital, Oslo, Norway.
Abstract
BACKGROUND: This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern platinum-based chemotherapy. PATIENTS AND METHODS: Eligible TCS were <55 years of age at diagnosis and treated with first-line platinum-based chemotherapy. Participants underwent physical examinations and completed questionnaires regarding 15 AHOs and health behaviors. Hypogonadism was defined as serum testosterone levels ≤3.0 ng/mL or use of testosterone replacement therapy. We investigated the role of 2 single nucleotide polymorphisms (rs6258 and rs12150660) in the sex hormone-binding globulin (SHBG) locus implicated in increased hypogonadism risk in the general population. RESULTS: Of 491 TCS (median age at assessment, 38.2 years; range, 18.7-68.4 years), 38.5% had hypogonadism. Multivariable binary logistic regression analysis identified hypogonadism risk factors, including age at clinical evaluation (odds ratio [OR], 1.42 per 10-year increase; P= .006) and body mass index of 25 to <30 kg/m2 (OR, 2.08; P= .011) or ≥30 kg/m2 (OR, 2.36; P= .005) compared with <25 kg/m2. TCS with ≥2 risk alleles for the SHBG SNPs had a marginally significant increased hypogonadism risk (OR, 1.45; P= .09). Vigorous-intensity physical activity appeared protective (OR, 0.66; P= .07). Type of cisplatin-based chemotherapy regimen and socioeconomic factors did not correlate with hypogonadism. Compared with TCS without hypogonadism, those with hypogonadism were more likely to report ≥2 AHOs (65% vs 51%; P= .003), to take medications for hypercholesterolemia (20.1% vs 6.0%; P<.001) or hypertension (18.5% vs 10.6%; P= .013), and to report erectile dysfunction (19.6% vs 11.9%; P= .018) or peripheral neuropathy (30.7% vs 22.5%; P= .041). A marginally significant trend for increased use of prescription medications for either diabetes (5.8% vs 2.6%; P= .07) or anxiety/depression (14.8% vs 9.3%; P= .06) was observed. CONCLUSIONS: At a relatively young median age, more than one-third of TCS have hypogonadism, which is significantly associated with increased cardiovascular disease risk factors, and erectile dysfunction. Providers should screen TCS for hypogonadism and treat symptomatic patients.
BACKGROUND: This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern platinum-based chemotherapy. PATIENTS AND METHODS: Eligible TCS were <55 years of age at diagnosis and treated with first-line platinum-based chemotherapy. Participants underwent physical examinations and completed questionnaires regarding 15 AHOs and health behaviors. Hypogonadism was defined as serum testosterone levels ≤3.0 ng/mL or use of testosterone replacement therapy. We investigated the role of 2 single nucleotide polymorphisms (rs6258 and rs12150660) in the sex hormone-binding globulin (SHBG) locus implicated in increased hypogonadism risk in the general population. RESULTS: Of 491 TCS (median age at assessment, 38.2 years; range, 18.7-68.4 years), 38.5% had hypogonadism. Multivariable binary logistic regression analysis identified hypogonadism risk factors, including age at clinical evaluation (odds ratio [OR], 1.42 per 10-year increase; P= .006) and body mass index of 25 to <30 kg/m2 (OR, 2.08; P= .011) or ≥30 kg/m2 (OR, 2.36; P= .005) compared with <25 kg/m2. TCS with ≥2 risk alleles for the SHBG SNPs had a marginally significant increased hypogonadism risk (OR, 1.45; P= .09). Vigorous-intensity physical activity appeared protective (OR, 0.66; P= .07). Type of cisplatin-based chemotherapy regimen and socioeconomic factors did not correlate with hypogonadism. Compared with TCS without hypogonadism, those with hypogonadism were more likely to report ≥2 AHOs (65% vs 51%; P= .003), to take medications for hypercholesterolemia (20.1% vs 6.0%; P<.001) or hypertension (18.5% vs 10.6%; P= .013), and to report erectile dysfunction (19.6% vs 11.9%; P= .018) or peripheral neuropathy (30.7% vs 22.5%; P= .041). A marginally significant trend for increased use of prescription medications for either diabetes (5.8% vs 2.6%; P= .07) or anxiety/depression (14.8% vs 9.3%; P= .06) was observed. CONCLUSIONS: At a relatively young median age, more than one-third of TCS have hypogonadism, which is significantly associated with increased cardiovascular disease risk factors, and erectile dysfunction. Providers should screen TCS for hypogonadism and treat symptomatic patients.
Authors: T J Postma; N K Aaronson; J J Heimans; M J Muller; J G Hildebrand; J Y Delattre; K Hoang-Xuan; M Lantéri-Minet; R Grant; R Huddart; C Moynihan; J Maher; R Lucey Journal: Eur J Cancer Date: 2005-04-14 Impact factor: 9.162
Authors: M T Meinardi; J A Gietema; W T van der Graaf; D J van Veldhuisen; M A Runne; W J Sluiter; E G de Vries; P B Willemse; N H Mulder; M P van den Berg; H S Koops; D T Sleijfer Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Henry A Feldman; Christopher Longcope; Carol A Derby; Catherine B Johannes; Andre B Araujo; Andrea D Coviello; William J Bremner; John B McKinlay Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Andreas G Wibmer; Paul C Dinh; Lois B Travis; Carol Chen; Maria Bromberg; Junting Zheng; Marinela Capanu; Howard D Sesso; Darren R Feldman; Hebert Alberto Vargas Journal: JNCI Cancer Spectr Date: 2022-07-01